Document is current
Any future updates will be listed below
-
Authors
Mandel, Jacob E.
Kim, DaeHee
Yarmohammadi, Hooman
Ziv, Etay
Keohan, Mary L.
D’Angelo, Sandra P.
Gounder, Mrinal M.
Whiting, Karissa
Qin, Li-Xuan
Singer, Samuel
Crago, Aimee M.
Erinjeri, Joseph P.
- License Information
-
More Information
Article History
Received: 26 May 2020
Accepted: 29 June 2021
First Online: 16 July 2021
Disclosure
: Etay Ziv has received research Grants from SIR, RSNA, NANETS, MSK Functional Genomics Initiative, MSK Society, Cycle For Survival, AACR-NETR, and Druckenmiller; Sandra D'Angelo is a consultant/advisor for Amgen, EMD Serono, GlaxoSmithKline, Immune Design, Incyte, Merck & Co., Nektar, Immunocore, and Pfizer; has received grants from Amgen, EMD Serono, Incyte, Merck & Co., Nektar, Bristol-Myers Squibb, and Deciphera; and has received reimbursement for travel and accommodation expenses from EMD Serono, Merck & Co, Adaptimmune, and Immunocore. Mrinal Gounder is a paid consultant for Bayer (use of sorafenib in desmoid tumors) and Springworks Therapeutics (use of investigational drug in desmoid tumors). Jacob E. Mandel, DaeHee Kim, Hooman Yarmohammadi, Mary L. Keohan, Karissa Whiting, Li-Xuan Qin, Samuel Singer, and Joseph P. Erinjeri have no conflicts of interest to declare
